The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps

Gayatri B. Patel, Anju T. Peters*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

2 Scopus citations


Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.

Original languageEnglish (US)
Pages (from-to)44-47
Number of pages4
JournalEar, Nose and Throat Journal
Issue number1
StatePublished - Jan 2021


  • benralizumab
  • biologics
  • chronic rhinosinusitis with nasal polyps (CRSwNP)
  • dupilumab
  • mepolizumab
  • nasal polyps
  • omalizumab

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps'. Together they form a unique fingerprint.

Cite this